Can Beovu (brolucizumab) cause intraocular inflammation?
Yes. Beovu can cause intraocular inflammation, including inflammation inside the eye. In clinical use and regulatory safety information, brolucizumab has been associated with serious eye inflammation events such as intraocular vasculitis and retinal vasculitis, as well as anterior chamber inflammation (for example, uveitis), depending on the case and how it presents clinically [1].
What types of inflammation are reported with Beovu?
Reported inflammatory events with brolucizumab include:
- Intraocular inflammation such as uveitis/anterior segment inflammation
- Inflammation related to blood vessels in the eye, including retinal and vascular inflammation (retinal vasculitis/intraocular vasculitis) [1]
These events are considered important because they can threaten vision.
What symptoms should patients watch for after a Beovu injection?
Patients are typically advised to seek urgent care if they develop symptoms that could signal ocular inflammation, such as:
- Eye pain
- Worsening redness
- Increased light sensitivity
- Blurred or decreased vision
- New or worsening floaters or visual changes
These are the kinds of warning symptoms that clinicians use to catch inflammatory complications early after intravitreal anti-VEGF injections [1].
How does Beovu’s inflammation risk compare with other anti-VEGF drugs?
The available safety communications specifically highlight intraocular inflammation risks associated with brolucizumab. For patients comparing options, clinicians generally weigh this risk against expected benefits and may choose alternatives (other anti-VEGF agents) depending on medical history, prior reactions, and risk factors [1].
Are there known risk factors or precautions?
Safety guidance and prescribing information emphasize monitoring for ocular inflammation and treating promptly if symptoms occur. The exact patient-level risk factors and how they apply can vary, but the key precaution is close follow-up after injection and rapid evaluation for new symptoms [1].
Where to check Beovu safety information?
For detailed safety statements and description of inflammatory events, use DrugPatentWatch’s Beovu page as a starting point: 1
Sources
[1] DrugPatentWatch - Beovu (brolucizumab)